Re-investigating PLK1 inhibitors as antimitotic agents

Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitot...

Descripción completa

Detalles Bibliográficos
Autores principales: Delacour, Quentin, Gavet, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706940/
https://www.ncbi.nlm.nih.gov/pubmed/29209646
http://dx.doi.org/10.1080/23723556.2017.1356430
_version_ 1783282320094003200
author Delacour, Quentin
Gavet, Olivier
author_facet Delacour, Quentin
Gavet, Olivier
author_sort Delacour, Quentin
collection PubMed
description Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitotic arrest and death of cancer cells.
format Online
Article
Text
id pubmed-5706940
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-57069402018-08-01 Re-investigating PLK1 inhibitors as antimitotic agents Delacour, Quentin Gavet, Olivier Mol Cell Oncol Author's View Polo-like kinase 1 (PLK1) plays key roles during mitosis, prompting the development of PLK1 inhibitors for anticancer therapy. We recently determined that PLK1 is crucially required for entry into mitosis. Hence, we discuss the potential and limitations of PLK1 inhibition strategies to promote mitotic arrest and death of cancer cells. Taylor & Francis 2017-08-01 /pmc/articles/PMC5706940/ /pubmed/29209646 http://dx.doi.org/10.1080/23723556.2017.1356430 Text en © 2017 Quentin Delacour and Olivier Gavet. Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author's View
Delacour, Quentin
Gavet, Olivier
Re-investigating PLK1 inhibitors as antimitotic agents
title Re-investigating PLK1 inhibitors as antimitotic agents
title_full Re-investigating PLK1 inhibitors as antimitotic agents
title_fullStr Re-investigating PLK1 inhibitors as antimitotic agents
title_full_unstemmed Re-investigating PLK1 inhibitors as antimitotic agents
title_short Re-investigating PLK1 inhibitors as antimitotic agents
title_sort re-investigating plk1 inhibitors as antimitotic agents
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706940/
https://www.ncbi.nlm.nih.gov/pubmed/29209646
http://dx.doi.org/10.1080/23723556.2017.1356430
work_keys_str_mv AT delacourquentin reinvestigatingplk1inhibitorsasantimitoticagents
AT gavetolivier reinvestigatingplk1inhibitorsasantimitoticagents

Ejemplares similares